乙型肝炎肝硬化患者并发急性肾损伤危险因素分析*

doi:10.3969/j.issn.1672-5069.2021.06.029

摘要/Abstract

摘要： 目的分析探讨乙型肝炎肝硬化患者并发急性肾损伤(AKI)的危险因素。方法 2018年3月～2020年3月于我院进行治疗的乙型肝炎肝硬化患者136例,通过电子病历收集一般资料和实验室指标,根据相关标准诊断诊断并发AKI者40例,无AKI者96例。应用Logistic回归分析影响AKI发生的危险因素。结果单因素分析结果表明,并发AKI患者失代偿期肝硬化占比为52.5%,显著高于无AKI患者的31.3%(P<0.05),腹水发生率为55.0%,显著高于无AKI患者的29.2%(P<0.05),并发肝性脑病发生率为22.5%,显著高于无AKI患者的4.2%(P<0.05),而两组性别、年龄、病程、Child-Pugh分级差异无统计学意义(P>0.05);多元Logistic回归分析结果显示肝硬化分期、腹水和并发肝性脑病是乙型肝炎肝硬化患者发生AKI的独立危险因素(P<0.05)。结论乙型肝炎肝硬化患者发生肝功能失代偿、腹水或并发肝性脑病容易诱发AKI,临床需要行针对性的预防措施,以提高生存率。

关键词: 肝硬化, 急性肾损伤, 危险因素, 多因素分析

Abstract: Objective The purpose of this study was to analyze the risk factors of acute kidney injury (AKI) in patients with hepatitis B-induced liver cirrhosis (LC). Methods 136 patients with hepatitis B-induced LC were admitted to our hospital between March 2018 and March 2020, and the clinical data were retrieved from HIS system. The AKI in 40 patients was diagnosed met with related guidelines, and the Logistic regression was applied to analyze the risk factors that affect the occurrence of AKI. Results The univariate analysis showed that the percentage of decompensated liver cirrhosis in patients with AKI was 52.5%, significantly higher than 31.3%(P<0.05) in those without, the incidence of ascites was 55.0%, significantly higher than 29.2%(P<0.05) in patients without AKI, and the hepatic encephalopathy was 22.5%, significantly higher than 4.2%(P<0.05) in those without, while there were no significant differences respect to age, gender, disease course and Child-Pugh class between the two groups (P>0.05); the multivariate Logistic regression analysis showed that compensated or decompensated liver functions, ascites, and hepatic encephalopathy were the independent risk factors for AKI occurrence in patients with hepatitis B-induced LC (P<0.05). Conclusion The patients with hepatitis B-induced LC might have AKI, especially in those with risk factors such as decompensated liver cirrhosis, ascites and complicated hepatic encephalopathy.

Key words: Liver cirrhosis, Acute kidney injury, Risk factors, Multivariate Logistic regression analysis

韩成美, 韩永峰, 王春华. 乙型肝炎肝硬化患者并发急性肾损伤危险因素分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 883-886.

Han Chengmei, Han Yongfeng, Wang Chunhua. Risk factors for acute kidney injury in patients with hepatitis B-induced liver cirrhosis[J]. Journal of Practical Hepatology, 2021, 24(6): 883-886.

参考文献

[1] Han Y,Zeng A, Liao H, et al. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: a systematic review and meta-analysis. Int Immunopharmacol,2017,42:168-175.
[2] Zhang J, Wen XY,Gao RP. Hepatitis B virus-related liver cirrhosis complicated with dermatomyositis: A case report. World J Clin Cases, 2019,7(10):1206-1212.
[3] Lian JS, Zhang XL, Lu YF, et al. Switching lamivudine with adefovir dipivoxil combination therapy to entecavir monotherapy provides better viral suppression and kidney safety. Int J Med Sci, 2019,16(1):17-22.
[4] Zheng H, Liu H, Hao A, et al. Association between serum cystatin C and renal injury in patients with chronic hepatitis B. Medicine (Baltimore), 2020,99(32):e21551.
[5] Mori T,Ohsaki Y, Oba-Yabana I, et al. Diuretic usage for protection against end-organ damage in liver cirrhosis and heart failure. Hepatol Res, 2017,47(1):11-22.
[6] Kennedy L, Francis H,Invernizzi P, et al. Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis. FASEB J, 2019,(9):10269-10279.
[7] Muciño MJ. Mechanisms of kidney dysfunction in the cirrhotic patient: non-hepatorenal acute-on-chronic kidney damage considerations. Ann Hepatol,2020,19(2):145-152.
[8] 王贵强,王福生,成军,等.慢性乙型肝炎防治指南(2015年更新版).中华肝脏病杂志,2015,23(12):888-905.
[9] Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the international club of ascites. J Hepatol, 2015,62(4):968-974.
[10] MacDonald AJ, Nadim MK, Durand F, et al. Acute kidney injury in cirrhosis: implications for liver transplantation. Curr Opin Crit Care, 2019,25(2):171-178.
[11] Jiang QQ, Han MF, Ma K, et al. Acute kidney injury in acute-on-chronic liver failure is different from in decompensated cirrhosis. World J Gastroenterol, 2018,24(21):2300-2310.
[12] Angeli P, Gines P, Wong F, et al.International Club of Ascites. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut, 2015,64(4):531-537.
[13] Deep A, Saxena R, Jose B. Acute kidney injury in children with chronic liver disease. Pediatr Nephrol,2019,34(1):45-59.
[14] Kellum JA, Prowle JR. Paradigms of acute kidney injury in the intensive care setting. Nat Rev Nephrol, 2018,14(4):217-230.
[15] Wang Y, Bellomo R. Cardiac surgery-associated acute kidney injury: risk factors, pathophysiology and treatment. Nat Rev Nephrol, 2017,13(11):697-711.
[16] Mohrer D, Langhan M. Acute kidney injury in pediatric patients: Diagnosis and management in the emergency department. Pediatr Emerg Med Pract, 2017, 14(5):1-24.
[17] Ul Abideen Z, Mahmud SN, Salih M, et al. Contrast-induced acute kidney injury in patients with liver cirrhosis: a retrospective analysis. Cureus, 2018,10(5):e2707.
[18] Bonavia A, Singbartl K. Kidney injury and electrolyte abnormalities in liver failure. Semin Respir Crit Care Med, 2018,39(5):556-565.
[19] Zhong HJ, Sun HH, Xue LF, et al. Differential hepatic features presenting in Wilson disease-associated cirrhosis and hepatitis B-associated cirrhosis. World J Gastroenterol, 2019,25(3):378-387.
[20] Stulic M, Culafic D, Obrenovic R, et al. The clinical importance of cystatin C and hepatic artery resistive index in liver cirrhosis. Medicina (Kaunas), 2018,54(3):37.
[21] Maiwall R, Pasupuleti SSR, Bihari C, et al. Incidence, risk factors, and outcomes of transition of acute kidney injury to chronic kidney disease in cirrhosis: a prospective cohort study. Hepatology, 2020,71(3):1009-1022.
[22] Wu J, Wu Q, Wu M, et al. Serum cystatin C predicts mortality in HBV-related decompensated cirrhosis. Biomed Res Int,2019,2019:7272045.
[23] Mauro E, Crespo G, Martinez-GA, et al. Cystatin C and sarcopenia predict acute on chronic liver failure development and mortality in patients on the liver transplant waiting list. Transplantation, 2020,104(7):e188-e198.
[24] Tripathi DM, Vilaseca M, Lafoz E, et al. Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension. Gastroenterology, 2018, 155(5):1564-1577.
[25] Garbuzenko DV, Arefyev NO, Kazachkov EL. Antiangiogenic therapy for portal hypertension in liver cirrhosis: current progress and perspectives. World J Gastroenterol, 2018,24(33):3738-3748.
[26] Clària J, Stauber RE, Coenraad MJ, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology, 2016, 64(4):1249-64.
[27] Shalapour S, Lin XJ, Bastian IN, et al. Inflammation-induced IgA⁺ cells dismantle anti-liver cancer immunity. Nature, 2017,551(7680):340-345.
[28] Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology, 2017,152(6):1297-1309.
[29] Wong GL. Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend. Clin Mol Hepatol, 2018, 24(2):108-113.
[30] 谯铭铭,王顺,李财昌,等.社区获得性与医院获得性急性肾损伤的临床特点和预后分析.中华肾脏病杂志,2016,32(1):16-23.

乙型肝炎肝硬化患者并发急性肾损伤危险因素分析^*

Risk factors for acute kidney injury in patients with hepatitis B-induced liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吴晓枫, 黄怡, 杨如杏, 邓少东, 张静莹, 官成浓, 王颖. 原发性胆汁性肝硬化患者外周血丝氨酸蛋白酶抑制剂A1基因多态性分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 855-858.
[2]	石翠翠, 刘彦君, 章瑞南, 李光明, 范建高. 肝硬化患者血脂异常分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 859-862.
[3]	柳梅, 时永红, 郇娟, 陈茂丽. 失代偿期肝硬化患者并发医院内感染病原菌类别及其耐药特点分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 863-866.
[4]	刘玉玲, 甄增国, 王慧娟, 万秀敏, 郭振凯. 益生菌制剂对肝硬化并发自发性细菌性腹膜炎患者肠道屏障功能的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 867-870.
[5]	邢莉, 杜倩影, 姜艳丽, 韩冬. 分段注射对比剂CT增强扫描提高乙型肝炎肝硬化患者肝静脉显影效果研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 871-874.
[6]	黄力鸥, 吴春荣, 徐丹, 崔宇慧, 唐建国. 无肝素化连续性肾脏替代治疗肝硬化并发肝性脑病患者疗效研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 875-878.
[7]	叶东, 张俊霞, 李洁, 刘颖, 张丹, 郭永泽. 内镜下食管静脉曲张套扎术治疗乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血患者再出血风险观察^*[J]. 实用肝脏病杂志, 2021, 24(6): 879-882.
[8]	王菁, 毕宁, 方亮, 田园. 自体骨髓干细胞经肝动脉肝内移植治疗失代偿期乙型肝炎肝硬化患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(6): 887-890.
[9]	薛魁, 徐银海, 张健. 慢性乙型肝炎和乙型肝炎肝硬化患者血清血小板生成素水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2021, 24(6): 891-894.
[10]	韩利畴, 许望, 韩丹, 邢增珀. 慢性乙型肝炎和乙型肝炎肝硬化患者胃粘膜病变研究[J]. 实用肝脏病杂志, 2021, 24(6): 895-898.
[11]	束青华, 张楠楠, 葛勇胜. 不同HCV基因型感染的慢性丙型肝炎和肝硬化患者对重组人干扰素α-2a治疗应答的影响[J]. 实用肝脏病杂志, 2021, 24(6): 899-902.
[12]	赵鹏飞, 祖红梅, 辛晓恩, 彭军宁, 严兆兰, 马存凯, 李雅静, 杨硕. 肝细胞癌发病危险因素Logistic回归分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 927-929.
[13]	邓江, 石娟娟, 党双锁. 男性慢性肝病患者勃起功能障碍研究进展^*[J]. 实用肝脏病杂志, 2021, 24(6): 934-937.
[14]	赵剑波, 谭卿. 非肝硬化性门静脉高压症研究进展[J]. 实用肝脏病杂志, 2021, 24(5): 613-616.
[15]	谭风雷, 吴亮亮, 邓泽润, 徐峥, 张洁, 张跃新. 夜间加餐对肝硬化患者影响的Meta分析[J]. 实用肝脏病杂志, 2021, 24(5): 625-628.